Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
India may issue a warning over cough syrup exported by Marion Biotech linked to a death in Uzbekistan.
Read Full NewsAvadel's REVITALYZ trial for Lumryz in idiopathic hypersomnia shows promise, potentially offering a new treatment option for this underserved condition.
NeurologyLive® provided in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.
Ophthalmology in 2025: Year in Review
Increases in Physician Attrition Rates Could Worsen Shortages
Hormonal Disorders in 2025: Year in Review
1.
Reversing the toxic relationship with high doses of chemotherapy in oncology.
2.
Study finds 81% of cancer cures touted by TikTok videos are fake
3.
A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.
4.
Non-small cell lung cancer patients who are ineligible for platinum-based chemotherapy benefit from atezolizumab monotherapy.
5.
Top Options Are Discovered Through Direct Comparison of 25 Migraine Drugs.
1.
Unpacking the Importance of White Blood Cells (WBCs) in the Body
2.
Uncovering the Mystery of the Sessile Serrated Adenoma
3.
Beyond the Biopsy: The Evolving Landscape of Prostate Cancer Management
4.
Precision Medicine and Genomics: Harnessing Longitudinal Data Modeling to Decode Cancer Progression
5.
Revolutionizing Cancer Treatment: ESMO's Updated Recommendations for Tumour NGS
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
5.
Updates on Standard V/S High Risk Myeloma Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge